14th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Turkey, 25 - 28 June 2024, pp.368
Introduction: Neurodegenerative diseases such as Alzheimer’s and Parkinson’s cause necrosis of neurons, loss of function, abnormal signal transmission between cells, inflammatory response and insulin dysfunction in the brain. It is estimated that this situation will affect approximately 150 million people globally in 2050 and cause an economic burden of 10 trillion dollars (Temple, 2023). It is thought that metformin, a guanidine-derived antidiabetic agent, may play a neuroprotective role by regulating energy metabolism, oxidative stress, inflammatory response, and preventing neuronal dysfunction and neuron death (Sharma et al., 2021; Du et al., 2022). This study aimed to investigate the neuroprotective effect of metformin against penicillin-induced neurotoxicity in the SH-SY5Y cell line.
Materials and Methods: After seeding SH-SY5Y cells, various concentrations of penicillin and metformin were applied, and at the end of 24 hours, neuronal viability test (MTT) was performed to decide the concentrations of penicillin and metformin for the study. The effect of metformin (10, 20, 40 mM) against penicillin (800 µM)-induced neurotoxicity in SH-SY5Y cells was tested with three different experimental designs (pre-treatment, co-treatment, post-treatment).
Results: Metformin (10, 20, 40 mM) showed a neuroprotective effect in pre-treatment and co-treatment experimental designs, while metformin (40 mM) showed a neuroprotective effect post treatment.
Conclusions: After this stage, we will continue to confirm the neuroprotective effect of metformin in our studies and focus on elucidating the underlying mechanisms.